Inhibrx Inc. (NASDAQ:INBX) saw an upside of 28.34% to $35.44 after adding $7.83 on Tuesday. The 5-day average trading volume is 294,428 shares of the company’s common stock. It has gained $36.57 in the past week. An average of 202,232 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 154,175.
INBX’s 1-month performance is -19.01% or $1.63 on its low of $26.39 reached on 10/08/21. The company’s shares have touched a 52-week low of $14.27 and high of $50.97, with the stock’s rally to the 52-week high happening on 02/09/21. YTD, INBX has lost -16.26% or $2.75. However, the current price is down -30.48%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Mar 24, 202 days have gone by since the last insider trading activity for Inhibrx Inc. (INBX). Eckelman Brendan P. (Chief Scientific Officer) most recently sold 17,000 shares at $19.02 per share on Mar 24. This transaction cost the insider $323,340. Chief Medical Officer, Wagner Klaus W., sold 19,559 shares at a price of $25.29 on Feb 17. Then, on Feb 16, Chief Scientific Officer Eckelman Brendan P. sold 17,000 shares at a price of $25.90 per share. This transaction amounted to $440,300.
Inhibrx Inc. (INBX) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.25 for the sector.INBX stock has a beta of 0.00. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 103.89 while the price-to-book (PB) in the most recent quarter is 23.60.
Inhibrx Inc.’s quick ratio for the period ended June 29 was 6.10, with the current ratio over the same period at 6.10 meaning that INBX stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 1.57, while the total debt to equity was 0.00The trailing 12-month EBITDA margin is -504.73%. The firm’s gross profit as reported stood at $80.33 million against revenue of $12.89 million.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected INBX to announce -$0.56 per share in earnings in its latest quarter, but it posted -$0.55, representing a 1.80% surprise. EBITDA for the quarter stood at more than -$19.27 million. INBX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 97.57 million, with total debt at $77.15 million. Shareholders hold equity totaling $37.89 million
Let’s look briefly at Inhibrx Inc. (INBX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 63.97% to suggest the stock is trending Neutral, with historical volatility in this time period at 149.26%.
The stock’s 5-day moving average is $29.23, reflecting a +21.62% or $6.35 change from its current price. INBX is currently trading +2.44% above its 20-day SMA, +114.28% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +27.85% and -19.37% respectively.
Stochastic %K and %D was 30.33% and 12.89% and the average true range (ATR) pointed at 2.97. The RSI (14) points at 59.83%, while the 14-day stochastic is at 77.81% with the period’s ATR at 2.71. The stock’s 9-day MACD Oscillator is pointing at -0.24 and -2.25 on the 14-day charts.
In the most recent analyst report for Inhibrx Inc. (NASDAQ: INBX), JMP Securities launched coverage with a Mkt outperform rating. Analysts offering their rating for INBX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate INBX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 5 have offered a “buy” rating.
What is INBX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $38.00 and a high of $50.00, with their median price target at $44.00. Looking at these predictions, the average price target given by analysts is for Inhibrx Inc. (INBX) stock is $43.60.